Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516440 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Site LicenseAdd to Basket
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket
Live Chat Live Help Software for Website

Global Biopharma Outlook 2012 - India Pharma

MP Advisors, Jan 2012, Pages: 38


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

Global Biopharma Outlook 2012: India Pharma

Growth Drivers for India Pharma: Para IV and Domestic market

Domestic Formulations –

- Regulatory Reforms on manufacturing, marketing and distribution
- Impact of regulatory reforms on consolidation
- Recent reforms and its impact
- Draft Drug Pricing Policy – Analysis and Impact

Para IV Opportunity –

- Expected New Generics in 2012, 2013 and 2014
- Indian companies’ comprehensive list of likely 180-day exclusivities.
- Likely forfeiture of exclusivities

Investment Recommendations on

- Aurobindo
- Biocon
- Cadila
- Cipla
- Dishman
- Dr Reddy’s
- Ipca
- Lupin
- Ranbaxy
- Sun Pharma



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds